PerkinElmer, Inc.
Apr 9, 2010
PDF

PerkinElmer’s New LANCE® Ultra cAMP Detection Kit Facilitates Screening of Complex G-Protein Coupled Receptors for Therapeutic Research

PHOENIX - SBS 2010 - PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced the launch of its new LANCE® Ultra cAMP Detection Kit. Designed for screening and profiling of G-protein coupled receptors (GPCRs) as tools in the search for potential therapeutics, the LANCE® Ultra kit offers three times the sensitivity using at least 80 percent fewer cells than other kits currently on the market.

The new LANCE offering enhances PerkinElmer's position as the industry leader in providing quality assays for high throughput screening and profiling of GPCRs. This new kit facilitates pharmacological studies of challenging receptors involved in several diseases, including cancer and inflammatory, metabolic and neurodegenerative disorders.

"As the drug discovery processes continue to evolve, there is an increased demand for more robust and highly sensitive methods of measuring responses to GPCRs, which currently form over 40 percent of all drug targets. We've addressed this need with the new LANCE Ultra cAMP detection kit. Researchers can now take advantage of a wider assay window and dynamic range that provides for more accurate results, even when miniaturizing protocols for the most 'difficult to screen' targets, including Gi-coupled GPCR antagonist assays," said Martina Bielefeld-Sévigny, PhD, vice president and general manager, Drug Discovery and Research Reagent Solutions, Bio-discovery, PerkinElmer.

The increased sensitivity of the LANCE Ultra cAMP Detection Kit enables scientists to detect low levels of cAMP without the need to re-engineer cell lines, saving time and resources. This assay uses a simple and proven TR-FRET protocol for easy and precise adoption in a range of HTS applications, including 1,536-well formats. Furthermore, as many high throughput assays fail to generate reproducible data when cAMP levels are very low, the new kit maximizes signal stability and provides new insights into GPCRs.

LANCE Ultra utilizes PerkinElmer's proprietary ULight™ emission dye, for high efficiency and excellent signal-to-noise ratios. LANCE Ultra is optimized for use in high throughput and ultra high throughput screening applications for detection and analysis of protein activity for research purposes.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.8 billion in 2009 has around 8,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

Media Contacts:

Kim McCrossen
Phone: (781) 663-5871
Email: kim.mccrossen@perkinelmer.com